CNS Market Access in India: Government investment into CNS services set to stimulate market growth

Introduction

India's growing elderly population and expanding middle class population makes the country an attractive market for manufacturers of CNS products. Indeed, the number of CNS drugs approved grew steadily over 1999-2009. Key CNS drug launches to have taken place in India in recent years include ramelteon, rasagiline, desvenlafaxine extended release and paliperidone extended release.

Features and benefits

* Quantify the prevalent cases of key CNS conditions in India in 2010.
* Review the current treatment of key CNS conditions in India and published treatment guidelines.
* Identify the major multinational and domestic players in the Indian CNS market. Understand the composititon of their CNS portfolios.
* Examine the major strengths and weaknesses of the current Indian CNS market. Understand the key opportunites and threats facing developers.
* This report is authored by an analyst and epidemiologist based in Hyderabad, India.

Highlights

Stigma attached to psychiatric conditions in India deters patient presentation, resulting in underdiagnosis and undertreatment of mental health conditions. In addition, delivery of neurological, psychiatric and pain services in India are hampered by a severe shortage of professionals qualified to treat central nervous system (CNS) disorders.
The Indian government's increasing focus on mental illness and the implementation of the National Mental Health Programme represent key opportunities for multinational pharmaceutical companies seeking to penetrate the Indian market with a strong portfolio of CNS drugs.
The Indian CNS market is attractive to drug developers on account of the country’s growing elderly population. Since several CNS conditions (such as Alzheimer’s disease, depression, epilepsy, and pain) are prevalent in the elderly population, growth of this population segment will present a sizable patient population for drug developers to target.

Your key questions answered

* How many prevalent cases of key CNS condititons are there in India? Which indication offers the greatest patient potential to developers?
* Which are the most active multinational and domestic pharmaceutical companies in the Indian CNS market?
* How are neurology, psychiatry and pain services organized and delivered in India? What are the typical patient care pathways for key CNS conditions?
* What are the key opportunities for existing and prospective players? What are the major threats to the uptake of CNS drugs in India?
* What strategies can companies implement in order to achieve maximum penetration in the Indian CNS market?
[Studien Infos ausblenden]

Executive Summary
Strategic scoping and focus
Datamonitor insight into the CNS market in India
Related reports
OVERVIEW
Catalyst
Summary
EPIDEMIOLOGY OF KEY CNS CONDITIONS IN INDIA
Key findings
Alzheimer’s disease
Prevalence
Epidemiologic data used in forecasting
Methods
Results
Epilepsy
Prevalence
Epidemiologic data used in forecasting
Methods
Results
Depression
Prevalence and stigma
Epidemiologic data used in forecasting
Methods
Results
Schizophrenia
Prevalence
Sources
Methods
Results
Cancer pain
Cancer and associated pain in India
Epidemiologic data used in forecasting
Methods
Results
TREATMENT OF KEY CNS CONDITIONS IN INDIA
Key findings
Introduction
Organization and delivery of CNS services in India
Neurological services
Psychiatry services
Pain services
Treatment guidelines for key CNS diseases in India
Treatment guidelines for Alzheimer’s disease
Treatment guidelines for epilepsy
Treatment guidelines for depression
Treatment guidelines for schizophrenia
Treatment guidelines for cancer pain
Patient care pathways for key CNS conditions in India
Alzheimer’s disease
Epilepsy
Depression
Schizophrenia
Cancer pain
Current market situation
The number of CNS drugs approved in India has steadily increased over 1999–2009
KEY COMPANIES ACTIVE IN THE INDIAN CNS MARKET
Key findings
Introduction
Multinational corporations
Novartis
Abbott
Domestic players
Domestic players dominate the CNS market in India
Sun Pharma
Intas
Recent deals and alliances in the CNS sector in India
Abbott’s acquisition of Piramal's Healthcare Solutions business represents the most sizeable deal of recent years
STRATEGIC RECOMMENDATIONS FOR MARKET ACCESS
Key findings
Key future target indications
Depression
Epilepsy
SWOT analysis of the Indian CNS market
Strengths
Weaknesses
Opportunities
Threats
Strategies for market penetration
Acquisition of a domestic player with expertise in the CNS therapy area
Forge links with the government and mental health organizations to launch educational campaigns
BIBLIOGRAPHY
Books and journal papers
Websites
Datamonitor reports
APPENDIX
Contributing experts
Report methodology
[Inhaltsverzeichnis ausblenden]